Glyphic Biotechnologies
Single-molecule proteomics for drug discovery
About
Glyphic Biotechnologies is developing a next-generation single-molecule protein sequencing platform that enables high-throughput proteomics for drug discovery and biological research. Its proprietary technology allows researchers to identify and analyze proteins at resolution and scale not achievable with existing mass spectrometry methods, accelerating the discovery of novel therapeutics.
Products
-
Protein Sequencing by Expansion platform
— Enables single-molecule proteome sequencing with precise discrimination of all 20 amino acids and PTMs.
Customer sectors: life science researchers, proteomics labs, biopharmaceutical companies
-
Sample Preparation Reagent Kits
— Functionalizes peptides by attaching initiating linkers to prepare samples for sequencing.
Customer sectors: proteomics labs, biotechnology researchers, clinical laboratories
-
Molecular Expansion Process
— Sequentially adds amino acids with uniform spacing to build ProSE molecules for sequencing.
Customer sectors: biotechnology researchers, proteomics labs
-
Amino Acid Sequencing Nanopore Technology
— Reads ProSE molecules via nanopores to discriminate amino acids and post-translational modifications.
Customer sectors: proteomics labs, biopharmaceutical companies, life science researchers
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Glyphic Biotechnologies — available to members.
